Immune Thrombocytopenia in US Clinical Practice: Incidence and Healthcare Utilization/Expenditures in the First 12 Months Following Diagnosis

Conclusion: The findings of this study suggest that nearly 20,000 persons are newly diagnosed with ITP each year in the US, and that ITP is much more common than previously reported. The findings also suggest that, among patients requiring formal medical care, the economic burden during the first 12 months following diagnosis is high, with US expenditures during this period totaling nearly $450 million.DisclosuresWeycker: Amgen: Research Funding. Grossman: Amgen: Research Funding. Hanau: Amgen: Research Funding. Wu: Amgen: Research Funding. Hatfield: Amgen: Employment, Equity Ownership. Sharma: Amgen: Employment, Equity Ownership. Bensink: Amgen: Employment, Equity Ownership. Chandler: Amgen: Employment, Equity Ownership. Tarantino: Amgen: Membership on an entity's Board of Directors or advisory committees; Centers for Disease Control and Prevention: Research Funding; Health Resources and Services Administration: Research Funding; Pfizer: Other: Reviews grants; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Grifols: Research Funding, Speakers Bureau; Genentech: Membership on an entity's Board of Directors or advisory committees; Shire: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Weycker, D., Grossman, A., Hanau, A., Wu, H., Hatfield, M., Sharma, A., Bensink, M. E., Chandler, D., Tarantino, M. D. Tags: 901. Health Services Research-Non-Malignant Conditions: Poster I Source Type: research